Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Targeting the hypoxia-inducible factor (HIF)-mediated pathway is a strategy for renal cell carcinoma (RCC) therapy.
• Vascular endothelial growth factor (VEGF) is a critical mediator of angiogenesis, tumor growth, and metastasis, induced by HIF.
• Functional differences in VEGF transcription between HIF-1alpha and HIF-2alpha in RCC remain unclear.

Purpose of the Study:

• To investigate the distinct roles of HIF-1alpha and HIF-2alpha in regulating VEGF gene induction in RCC.
• To analyze the impact of HIF subunit expression and VHL gene mutation status on VEGF production in RCC cell lines.

Main Methods:

• Analysis of a panel of human RCC cell lines.
• Assessment of HIF-1alpha protein expression, mRNA transcripts, and gene silencing mechanisms.
• Gene knockdown experiments targeting HIF-2alpha.
• Evaluation of VEGF production in relation to VHL gene mutation status.

Main Results:

• Loss of HIF-1alpha protein expression is common in RCC cell lines, linked to truncated transcripts and transcriptional silencing.
• HIF-2alpha regulates VEGF production in HIF-1alpha-deficient RCC cells, regardless of VHL mutation status.
• HIF-1alpha predominantly drives VEGF secretion in RCC cells expressing both wild-type HIF-1alpha and HIF-2alpha.

Conclusions:

• HIF-1alpha is a crucial target for RCC therapy when functional.
• HIF-2alpha emerges as a critical therapeutic target in HIF-1alpha-defective renal cancer cells.
• Understanding HIF subunit roles is essential for developing effective targeted therapies for RCC.